论文部分内容阅读
目的探讨不同剂量的阿托伐他汀对急性冠脉综合症(ACS)患者血浆氧化型低密度脂蛋白(ox-LDL)及超敏C-反应蛋白(hs-CRP)的影响。方法以120例经临床症状和/或冠脉造影确定为ACS的患者为研究对象,根据阿托伐他汀剂量的不同随机分为阿托伐他汀常规剂量组(20 mg/d,60例)和阿托伐他汀大剂量组(40 mg/d,60例),分别于入院24 h内及服药后1周、2周测定两组患者的ox-LDL及hs-CRP水平,并进行比较。结果治疗前、治疗后1周、治疗后2周两组的ox-LDL水平分别为[常规剂量组:(0.62±0.12)mg/L,(0.47±0.14)mg/L,(0.33±0.13)mg/L;大剂量组:(0.63±0.15)mg/L,(0.41±0.11)mg/L,(0.21±0.15)mg/L];两组的hs-CRP水平为[常规组:(17.62±1.90)mg/L,(8.81±2.6)mg/L,(6.22±0.87)mg/L;大剂量组:(17.81±2.42)mg/L,(7.24±3.82)mg/L,(3.88±0.81)mg/L]。治疗前两组的ox-LDL及hs-CRP差异无统计学意义(P>0.05),治疗后1周、2周二者的水平较治疗前均明显下降(P<0.01),但是大剂量组下降水平较常规治疗组更显著(P<0.05)。结论大剂量的阿托伐他汀能更有效降低ACS患者的ox-LDL及hs-CRP的水平。
Objective To investigate the effects of different doses of atorvastatin on plasma oxidized low density lipoprotein (ox-LDL) and high-sensitivity C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS) Methods A total of 120 patients with ACS diagnosed by clinical symptoms and / or coronary angiography were enrolled in this study. Patients were randomized into atorvastatin (20 mg / d, 60 cases) and conventional atorvastatin Atorvastatin high-dose group (40 mg / d, 60 cases), ox-LDL and hs-CRP levels in two groups were measured 24 h after admission and 1 week and 2 weeks after treatment, respectively, and compared. Results The levels of ox-LDL in the two groups before treatment, 1 week after treatment and 2 weeks after treatment were respectively [0.62 ± 0.12] mg / L, (0.47 ± 0.14) mg / L and (0.33 ± 0.13) (0.63 ± 0.11) mg / L, (0.21 ± 0.15) mg / L]; the hs-CRP level in the two groups was [normal group: (17.62 (1.82 ± 0.87) mg / L, (1.81 ± 2.42) mg / L, (3.88 ± 2.82) mg / L, 0.81) mg / L]. The levels of ox-LDL and hs-CRP in the two groups before treatment were not significantly different (P> 0.05). The levels of the two groups were significantly decreased at 1 week and 2 weeks after treatment (P <0.01), but decreased in the high-dose group The level was more significant than the conventional treatment group (P <0.05). Conclusions High-dose atorvastatin can effectively reduce the levels of ox-LDL and hs-CRP in ACS patients.